Overviewįlumazenil is a benzodiazepine receptor antagonist that is FDA approved for the treatment of reversal of conscious sedation induced with benzodiazepines. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. Associate Editor(s)-in-Chief: Gloria Picoy Disclaimer Higher doses could be more effective in some patients, but it should also be verified in a placebo-controlled trial.Editor-In-Chief: C. Flumazenil, administered at a dose usually active against BZD sedation, does not improve CNS depression induced by ALC intoxication. However, an open administration of higher doses of flumazenil (2-5 mg) in 11 ALC patients, whose condition had not initially improved, was followed by clear improvement of consciousness in five of them. In the 18 ALC patients, 1 mg flumazenil was not more effective than placebo, whereas it appeared to be very active in the BZD group. A modified Glasgow score was used to observe the evolution of consciousness. Patients admitted in the emergency department with coma related to acute alcohol (ALC) or pure benzodiazepine (BZD) intoxication were randomized and treated blindly with either placebo or 1 mg flumazenil. Several isolated observations and short uncontrolled series have also suggested a possible effect against the impairment of consciousness induced by pure alcohol intoxication.
Flumazenil acts as an antidote for pharmacological and toxic effects due to benzodiazepines.